Adicet Bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACET Nasdaq 2834 www.adicetbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adicet Bio, Inc.

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - May 6th, 2025 8:01 pm
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Apr 30th, 2025 8:47 pm
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference - Apr 30th, 2025 11:00 am
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Apr 28th, 2025 8:30 pm
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate - Apr 27th, 2025 1:31 pm
Adicet Bio Appoints Michael Grissinger to the Board of Directors - Apr 17th, 2025 11:00 am
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference - Mar 31st, 2025 11:00 am
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts - Mar 23rd, 2025 12:43 pm
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress - Mar 6th, 2025 9:01 pm
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - Mar 3rd, 2025 12:00 pm
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 - Feb 27th, 2025 1:36 pm
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Feb 27th, 2025 12:00 pm
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Feb 5th, 2025 12:10 pm
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Jan 29th, 2025 12:00 pm
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Jan 8th, 2025 9:10 pm
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Dec 31st, 2024 9:48 pm
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Dec 19th, 2024 12:00 pm
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Dec 18th, 2024 12:00 pm
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Nov 18th, 2024 9:00 pm
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Nov 18th, 2024 12:00 pm